Back to Journals » Biologics: Targets and Therapy » Volume 13

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Total article views   Abstract views HTML views PDF downloads Totals
7,935 Dovepress* 6,905 638+ 647 7,543
PubMed Central* 0 392 99 392
Totals 6,905 1,030 746 7,935
*Since 25 November 2019
+Since July 2016

View citations on PubMed Central and Google Scholar